Abivax SA EURONEXT:ABVX:
ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL ADSS, BRINGING GROSS PROCEEDS OF OFFERING TO $920M (€807M)
TOTAL 7.36 MILLION ADSS ISSUED; GROSS PROCEEDS $920 MILLION, NET PROCEEDS $874.1 MILLION
PROCEEDS TO BE USED FOR POTENTIAL COMMERCIALIZATION OF OBEFAZIMOD IN U.S. AND CLINICAL RESEARCH EXPENSES
ADDITIONAL ADSS EXPECTED TO BE DELIVERED WITH OFFERING CLOSING ON JULY 6, 2026